Cardinal Health Completes Acquisition of Cordis

October 5, 2015—Cardinal Health announced that it has completed the acquisition of Johnson & Johnson's Cordis business for $1.944 billion. Cordis products will continue to be sold under the Cordis brand name, but with a logo that identifies Cordis as a Cardinal Health company.

The acquisition of Cordis’ portfolio of cardiology and endovascular products will strengthen Cardinal Health's offerings in the cardiovascular, wound management, and orthopedics areas, stated the company.

According to Cardinal Health, integration teams have been engaged since the acquisition announcement in March 2015, and the integration process is off to a successful start, with approximately 3,000 employees joining Cardinal Health when all integration work and transitions are completed over the next few years. David J. Wilson remains as Cordis’ worldwide President, and other executives are in place across all functions and regions. The business will report to Don Casey, Cardinal Health's Medical Segment Chief Executive Officer.

The Cordis team will remain based in the San Francisco Bay area of California. In addition, the organization will have operations in countries around the world, including global headquarters and a European, Middle Eastern, and African hub, which have been established in Zug, Switzerland. Singapore will serve as the Asian-Pacific hub, and Puerto Rico will serve as the Latin American hub, advised the company.